Welcome to our dedicated page for Sutro Biopharma news (Ticker: STRO), a resource for investors and traders seeking the latest updates and insights on Sutro Biopharma stock.
Sutro Biopharma develops next-generation antibody-drug conjugates for oncology through a cell-free protein engineering platform. Recurring company news covers single- and dual-payload ADC design, pipeline programs such as STRO-004, STRO-006 and STRO-227, and preclinical data across tissue factor, ITGB6 and PTK7-targeting programs.
Updates also address clinical and regulatory disclosures, research and development collaborations, operating results, financing activity, equity compensation matters, investor and scientific conference participation, and Nasdaq listing compliance. The coverage reflects Sutro’s focus on site-specific ADCs for solid tumors and other cancer indications with limited treatment options.
Sutro Biopharma (NASDAQ: STRO) reported Q1 2026 results and pipeline progress. Revenue was $14.5 million and R&D plus G&A expenses were $44.1 million. Cash, cash equivalents and marketable securities totaled $202.6 million, plus $110.0 million recent equity proceeds, extending cash runway into at least Q2 2028.
The company advanced ADC candidates STRO-004, STRO-006 and STRO-227, with initial STRO-004 Phase 1 data expected mid‑2026 and IND submissions for STRO-006 and STRO-227 planned in 2026. Under its Astellas collaboration, a TROP2 dual‑payload iADC entered the clinic, triggering a $10 million milestone. Sutro also closed its luvelta program.
Sutro Biopharma (NASDAQ: STRO) reported preclinical AACR 2026 results showing next-generation single- and dual-payload ADCs with robust antitumor activity across multiple solid tumor models.
Key points: STRO-004 showed tumor control at a single 5 mg/kg dose and HNSTD of 50 mg/kg; STRO-006 and STRO-227 demonstrated dose-dependent activity; STRO-227 IND planned for late 2026; STRO-004 Phase 1 results expected mid-2026. Partner Astellas’ TROP2 iADC ASP2998 is already dosing in clinic.
Sutro Biopharma (NASDAQ: STRO) reported full-year 2025 results and program updates. Key financials: $141.4M cash at December 31, 2025 and $102.5M 2025 revenue (vs. $62.0M in 2024). A $110.0M equity offering extends runway into at least Q2 2028.
Clinical highlights: three cohorts dosed in the Phase 1 STRO-004 program with initial data expected mid-2026; STRO-227 IND targeted for 2026; an Astellas-partnered iADC has entered the clinic, triggering near-term milestones.
Sutro Biopharma (NASDAQ: STRO) announced management participation in multiple investor conferences in early March 2026, including TD Cowen, Leerink Partners, Citizens Life Sciences, and Barclays.
Webcasts of fireside chats at TD Cowen and Citizens will be accessible via the company’s Events & Presentations page, with archived replays available for at least 30 days.
Sutro Biopharma (NASDAQ: STRO) will participate at the 16th World ADC London Summit in London, UK, February 23-26, 2026. Senior scientist Hans-Peter Gerber, Ph.D. will join panel discussions and present on dual-payload ADC efficacy and safety.
According to the company, plenary content will be posted in Sutro's Scientific Publications section after the event.
Sutro Biopharma (Nasdaq: STRO) priced an underwritten offering of 7,868,383 common shares at $13.98 per share, expected to raise approximately $110.0 million in gross proceeds before fees. The offering is expected to close on or about February 11, 2026.
Proceeds, together with existing cash and marketable securities, are intended primarily for general corporate purposes, including funding research, clinical and process development, manufacturing, working capital, and potential acquisitions or investments. Joint bookrunning managers include Leerink Partners, TD Cowen and LifeSci Capital.
Sutro Biopharma (NASDAQ: STRO) announced that Jane Chung, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026 at 11:15 AM PT / 2:15 PM ET in San Francisco.
A live webcast will be accessible via the Events & Presentations page of the Investor Relations section at www.sutrobio.com. An archived replay will be available for at least 30 days after the event.
Sutro Biopharma (NASDAQ: STRO) regained compliance with Nasdaq's minimum bid price requirement under Rule 5450(a)(1).
The Nasdaq Listing Qualifications Department confirmed on Dec 17, 2025 that, as of Dec 16, 2025, Sutro's common stock maintained an average closing price of at least $1.00 following the company's 1:10 reverse stock split that became effective on Dec 3, 2025. As a result, the company's shares are no longer considered below the minimum bid price requirement and the company has regained continued listing compliance.
Sutro Biopharma (NASDAQ: STRO) announced that on December 15, 2025 its Compensation Committee granted 24,500 stock options and 2,000 restricted stock units (RSUs) to new non-executive employees as inducement awards approved under Nasdaq Listing Rule 5635(c)(4).
The awards are governed by the Amended and Restated 2021 Equity Inducement Plan. Vesting for the stock options is 25% at one year then monthly to the fourth anniversary; RSU vesting is 25% at one year then annually to the fourth anniversary, each subject to continued service.
Sutro Biopharma (NASDAQ: STRO) announced dosing of the first cohort in its Phase 1 trial of STRO-004, a tissue factor (TF)–targeting exatecan ADC, on Dec 3, 2025. The open-label, multicenter dose-escalation study will evaluate safety, pharmacokinetics, and preliminary anti-tumor activity in advanced TF-expressing solid tumors including NSCLC, head and neck, cervical, colorectal, pancreatic ductal adenocarcinoma, and bladder cancer.
The program uses Sutro’s cell-free platform to enable site-specific ADCs and supports high entry doses backed by tolerability in non-human primates up to 50 mg/kg. Initial clinical data are expected in mid-2026, and the trial aims to identify a recommended Phase 2 dose rapidly. ClinicalTrials.gov ID: NCT07227168.